three
recent
scienc
articl
chen
et
al
gootenberg
et
al
myhrvold
et
al
describ
use
crisprca
technolog
develop
pointofcar
diagnost
directli
detect
virus
clinic
sampl
test
could
radic
transform
approach
diagnos
infecti
diseas
bedsid
field
zika
viru
zikv
everi
coupl
year
new
viru
emerg
hinterland
threaten
devast
popul
epidem
woefulli
unprepar
meet
urgent
need
fielddeploy
diagnost
test
guid
surveil
treatment
biocontain
effort
challeng
face
clinician
accur
diagnos
infect
extend
outbreak
field
also
routin
patient
care
commun
hospit
clinic
individu
molecular
test
vast
major
pathogen
typic
avail
except
sendout
assay
highli
special
refer
laboratori
pointofcar
diagnost
platform
rapid
flexibl
accur
detect
pathogen
directli
clinic
sampl
exist
three
paper
publish
scienc
chen
et
al
gootenberg
et
al
myhrvold
et
al
two
group
report
use
crisprcasbas
technolog
develop
molecular
diagnost
assay
focu
infecti
diseas
crisprca
system
bacteria
evolv
mechan
fight
virus
cleav
dna
rna
sequenc
invad
phage
hill
et
al
technolog
wide
repurpos
geneedit
applic
involv
famili
enzym
abl
precis
cleav
doublestrand
dna
dsdna
singlestrand
rna
ssrna
sequenc
complementari
guid
rna
purpos
detect
group
leverag
collater
activ
either
enzym
indiscrimin
cleav
ssrna
myhrvold
et
al
enzym
cleav
singlestrand
dna
ssdna
chen
et
al
guid
rna
activ
complementari
sequenc
cleavag
label
ssrna
ssdna
probe
gener
signal
provid
fluoresc
readout
number
portabl
format
includ
use
dispos
paper
strip
figur
sherlock
base
myhrvold
et
al
detectr
base
chen
et
al
assay
describ
paper
carri
sever
advantag
tradit
microbiolog
diagnost
nucleic
acid
amplif
test
eg
polymeras
chain
reaction
pcr
antigenbas
test
eg
immunostrip
drancourt
et
al
nucleic
acid
amplif
test
pcr
gener
consid
sensit
specif
test
avail
howev
test
typic
incorpor
multipl
step
run
assay
includ
upfront
nucleic
acid
extract
step
requir
dedic
instrument
contrast
group
demonstr
crisprcasbas
assay
run
directli
primari
clinic
sampl
singl
reaction
perform
use
minim
equip
assay
also
amen
use
lyophil
reagent
forego
need
mainten
cold
chain
thu
attract
use
field
howev
crisprca
assay
also
shown
exhibit
high
sensit
specif
detect
achiev
perform
compar
pcr
interestingli
may
due
fact
isotherm
amplif
still
requir
part
crisprcasbas
assay
protocol
gener
detect
fluoresc
signal
time
assay
similar
antigenbas
test
respect
eas
use
speed
sampletoansw
turnaround
time
hr
paper
myhrvold
et
al
work
deriv
collabor
two
promin
investig
broad
institut
feng
zhang
pardi
sabeti
author
illustr
sever
applic
sherlock
assay
includ
zikv
dengu
viru
denv
detect
directli
bodili
fluid
saliva
urin
hr
specif
discrimin
among
four
differ
denv
serotyp
identif
regionspecif
strain
zikv
pandem
detect
singlenucleotid
polymorph
recent
zikv
mutat
link
case
microcephali
affect
infant
yuan
et
al
last
two
exampl
particular
relev
public
health
epidemiolog
howev
clinic
util
assay
also
potenti
extrapol
individu
patient
determin
particular
hepat
c
viru
hcv
genotyp
guid
choic
antivir
therapi
aasldidsa
hcv
guidanc
panel
chen
et
al
paper
laboratori
jennif
doudna
uc
berkeley
author
use
detectr
assay
detect
highrisk
human
papillomaviru
type
associ
invas
genit
tumor
overal
accuraci
success
demonstr
extend
potenti
applic
crisprca
technolog
infecti
diseas
field
rapid
detect
singlenucleotid
polymorph
circul
tumor
cell
blood
instanc
may
usher
new
era
pointofcar
diagnost
earli
cancer
crisprcasbas
assay
also
leverag
use
companion
diagnost
treatment
exampl
broad
institut
group
describ
repair
mutat
apc
gene
link
famili
adenomat
polyposi
inherit
condit
greatli
increas
risk
colon
rectal
cancer
affect
individu
use
sherlock
simultan
genotyp
edit
apc
gene
human
embryon
kidney
cell
line
contain
insert
technolog
readi
prime
time
first
glanc
crisprcasbas
assay
appear
characterist
desir
pointofcar
diagnost
implement
singl
reaction
compat
lyophil
reagent
turnaround
time
design
flexibl
gener
new
assay
scratch
week
portabl
without
need
electr
expens
instrument
detect
directli
clinic
sampl
colorimetr
fluoresc
readout
assay
would
tremend
help
instanc
rapidli
deploy
avail
diagnost
test
earli
cours
west
african
ebov
zikv
epidem
howev
unlik
crisprca
approach
complet
solv
challeng
pointofcar
diagnost
test
fundament
assay
still
target
detect
test
use
specif
primer
probe
thu
subject
limit
deploy
test
emerg
outbreak
investig
may
use
caus
outbreak
known
exampl
cryptic
transmiss
circul
zikv
ongo
brazil
year
prior
initi
identif
may
faria
et
al
part
zikv
never
seen
america
consid
candid
outbreak
pathogen
priori
addit
high
specif
crisprca
cleavag
although
valu
target
diagnost
challeng
rna
virus
zikv
ebov
rapidli
mutat
inde
mutat
ebov
genom
like
result
decreas
sensit
perform
exist
pcr
assay
detect
makona
strain
caus
ebov
outbreak
west
africa
sozhamannan
et
al
field
infecti
diseas
diagnost
also
rapidli
move
toward
clinic
syndromicbas
multiplex
detect
use
target
panel
diagnos
neurolog
respiratori
gastrointestin
infect
ramanan
et
al
highli
multiplex
even
fulli
untarget
method
eg
metagenom
nextgener
sequenc
schlaberg
et
al
somasekar
et
al
may
prefer
diagnosi
unknown
acut
febril
ill
may
caus
varieti
differ
pathogen
instanc
signific
proport
patient
west
africa
ebov
outbreak
infect
lassa
fever
malaria
coinfect
note
diagnost
method
complementari
crisprcasbas
assay
may
use
initi
screen
antibiot
resist
exampl
reflex
sequenc
character
specif
gene
mechan
involv
forese
challeng
routin
implement
crisprcasbas
assay
includ
perform
cost
regulatori
issu
sinc
target
amplif
guid
rna
molecul
construct
target
specif
pathogen
tumor
cell
cancer
screen
collect
clinic
sampl
pointofcar
set
patient
bedsid
medic
offic
hospit
ward
field
assay
perform
directli
sampl
hr
without
need
separ
dna
rna
extract
step
note
protein
target
dsdna
target
rna
activ
protein
indiscrimin
cleavag
fluoresc
ssdna
probe
ssrna
probe
produc
detect
signal
numer
potenti
applic
crisprcasbas
assay
list
right
describ
text
step
still
incorpor
part
assay
remain
possibl
crosscontamin
andor
contamin
laboratori
reagent
environ
addit
reallif
perform
accuraci
crisprcasbas
diagnost
test
yet
known
especi
outsid
confin
control
laboratori
environ
also
remain
seen
whether
crisprcasbas
assay
standard
highthroughput
diagnost
test
view
regulatori
agenc
us
food
drug
administr
may
issu
regard
avail
cost
crisprcasbas
test
develop
world
especi
given
mani
intendedus
case
technolog
patent
final
key
consider
amen
approach
multiplex
current
paper
multiplex
one
target
parallel
demonstr
unknown
whether
upper
limit
number
target
success
incorpor
assay
nevertheless
despit
concern
crisprcasbas
technolog
provid
us
power
new
tool
perpetu
fight
infecti
diseas
